PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
about
Genetics and biology of pancreatic ductal adenocarcinomaTherapeutic potential of targeting acinar cell reprogramming in pancreatic cancerTargeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion.The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinomaPIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitorsRAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis.Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.Rho GTPases: Anti- or pro-neoplastic targets?KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis.The role of TGF-β and its crosstalk with RAC1/RAC1b signaling in breast and pancreas carcinoma.Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.The role of small GTPases of the Rho/Rac family in TGF-β-induced EMT and cell motility in cancer.Acinar cell plasticity and development of pancreatic ductal adenocarcinoma.Differentiation and Inflammation: 'Best Enemies' in Gastrointestinal Carcinogenesis.mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasiaOncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation.Luteolin inhibits pancreatitis‑induced acinar‑ductal metaplasia, proliferation and epithelial‑mesenchymal transition of acinar cells.The Rac GTPase in Cancer: From Old Concepts to New Paradigms.TSC1 regulates osteoclast podosome organization and bone resorption through mTORC1 and Rac1/Cdc42.MTOR inhibitor-based combination therapies for pancreatic cancer.Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar to Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.Regenerative proliferation of differentiated cells by mTORC1-dependent paligenosis.Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics.Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancerExome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations
P2860
Q26765438-FBFEECAF-C64D-4BB8-84B3-688748A98087Q28068998-F6858FA7-1721-4731-91D5-2A8027AF5D56Q35862596-029BA7E0-CFD1-43C7-9F49-A928A8D569F5Q35954277-988E55A2-1F4C-4A4D-9013-94733F73E407Q36245945-DB37E144-A70F-42BC-9395-7F39F947CBFAQ36398735-AE281046-BE9E-4F89-8AF1-73332F9E75ADQ37585776-0DD9D18C-EBA3-4B66-89E2-57CCA4A987FBQ38666705-6DC41AD6-2B81-40A1-93F0-5A620F66BEADQ38780866-7C151DD7-B39C-40C4-9008-963795AB95FFQ38786245-52363839-C4C2-46BB-8358-AB17C8E47F4DQ38788923-67AFB3BF-13FC-4E11-8A3F-555733AA3420Q38798291-F50932EA-F846-4189-8E01-23BB9E42A5B7Q38846822-B30D8CE1-1A24-49B6-84E5-BF392323CD4DQ38922230-E4D12668-9ADD-44F3-A0BF-F394A2FB4E8CQ39384816-9154E74C-8194-4FA4-9393-BAFA3BBCA899Q42359443-C73F6A05-3A19-41AA-80F9-309CFD2B4F52Q42457687-912C0820-A3BC-40BF-9717-DD1F11968AEBQ42564735-B872944E-4243-4190-B508-79B7AA8F5848Q47246517-E3DAC6A8-1F83-4FB6-AA27-D25EB23CEEA5Q47953335-C5C38CF1-1FDB-4322-B56A-0BB621FD41FCQ48527868-A44C71BB-EBD9-4431-A5B0-DE9C3E9EB409Q49560871-0F158AAC-881C-4F38-8738-CA694C4288D0Q49722539-77A2A50E-A7D5-4DFB-B38B-BB57E4E0840EQ49788157-FA6A2AA6-9861-485B-B02D-1D4D5DE29974Q50422422-BB979B1C-51E0-484A-A436-ED70D8A73DECQ54977145-A3A476C6-E00C-48E8-A6CC-64A705F20C81Q57494120-95F78610-429F-4B0C-94C4-E452CBA9FC8CQ58751735-DE6EBFC1-EF68-4B0B-A39C-90DA18D629CC
P2860
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@ast
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@en
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@nl
type
label
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@ast
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@en
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@nl
prefLabel
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@ast
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@en
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@nl
P2093
P2860
P1433
P1476
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
@en
P2093
Chanjuan Shi
Chia-Yen C Wu
Christopher J Halbrook
Eileen S Carpenter
Howard C Crawford
Jason C Hall
Kathleen E DelGiorno
Kenneth K Takeuchi
Louise V Peverley
Richard Z Lin
P2860
P304
1405-16.e7
P356
10.1053/J.GASTRO.2014.08.032
P407
P577
2014-08-27T00:00:00Z